Recombinant Anti-p53 antibody [Y5] (ab32049)
![Immunocytochemistry/ Immunofluorescence - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-17-anti-mutant-p53-tp53-y5-antibody-immunocytochemistry-hap1tp53-human.jpg "Immunocytochemistry/ Immunofluorescence - Anti-p53 antibody [Y5] (ab32049)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [Y5] to p53
- Suitable for: Flow Cyt (Intra), ICC/IF, WB, IHC-P, IP
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-p53 antibody [Y5]
See all p53 primary antibodies -
Description
Rabbit monoclonal [Y5] to p53 -
Host species
Rabbit -
Specificity
This antibody clone recognises both wild-type and mutant forms of p53 in human samples. It is not designed to recognise any specific p53 mutation.
We have confirmed this experimentally and have been able to detect p53 in different cell lines using various applications and treatments.
Important note: p53 expression levels vary greatly between cell lines. It has been reported that p53 mutations render the protein more stable, hence mutated cell lines often express higher levels of the p53 protein compared to wild-type cell lines. For low expressing wild type cell lines, p53 expression can be increased with cell treatments such as camptothecin or irinotecan.
-
Tested applications
Suitable for: Flow Cyt (Intra), ICC/IF, WB, IHC-P, IPmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- Wild type p53: A549, HEK293, HepG2, MCF7, U-87 MG. Mutant p53: A431 (R273H), DU 145 (P223L and V274F), HAP1 (S215G), Jurkat (R196*), MDA-MB-435 (G266E), Raji (R213Q and Y234H), Ramos (I254N), SK-BR-3 (R175H), T-47D (L194F). Cell lines expressing the highest levels of p53 without induction are HEK293 (WT p53), A431 and HAP1 (mutant p53). Negative cell line: Saos-2. IHC-P controls: Bladder, Skin Cancer, Glioma, Gastric adenocarcinoma, Human breast and lung carcinoma tissue, Human colon adenocarcinoma.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
Dissociation constant (KD)
KD = 2.02 x 10 -10 M Learn more about KD -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 49% PBS, 50% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
Y5 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Assay kits
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab32049 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Flow Cyt (Intra) |
Use at an assay dependent concentration.
|
|
| ICC/IF | (1) |
1/100.
|
| WB | (3) |
1/1000 - 1/5000. Detects a band of approximately 53 kDa (predicted molecular weight: 44 kDa).
|
| IHC-P |
1/50. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
|
| IP |
1/20.
|
| Notes |
|---|
|
Flow Cyt (Intra)
Use at an assay dependent concentration. |
|
ICC/IF
1/100. |
|
WB
1/1000 - 1/5000. Detects a band of approximately 53 kDa (predicted molecular weight: 44 kDa). |
|
IHC-P
1/50. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
|
IP
1/20. |
Target
-
Function
Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Implicated in Notch signaling cross-over. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. -
Tissue specificity
Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine. -
Involvement in disease
Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.
Defects in TP53 are a cause of esophageal cancer (ESCR) [MIM:133239].
Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.
Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC) [MIM:275355]; also known as squamous cell carcinoma of the head and neck.
Defects in TP53 are a cause of lung cancer (LNCR) [MIM:211980].
Defects in TP53 are a cause of choroid plexus papilloma (CPLPA) [MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood.
Defects in TP53 are a cause of adrenocortical carcinoma (ADCC) [MIM:202300]. ADCC is a rare childhood tumor of the adrenal cortex. It occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome and is a component tumor in Li-Fraumeni syndrome. -
Sequence similarities
Belongs to the p53 family. -
Domain
The nuclear export signal acts as a transcriptional repression domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) correspond both to 9aaTAD motifs which are transactivation domains present in a large number of yeast and animal transcription factors. -
Post-translational
modificationsAcetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence.
Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP.
Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.
May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line.
Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation. Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome. Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation. Deubiquitinated by USP10, leading to its stabilization. Ubiquitinated by TRIM24, which leads to proteasomal degradation. Ubiquitination by TOPORS induces degradation. Deubiquitination by USP7, leading to stabilization. Isoform 4 is monoubiquitinated in an MDM2-independent manner.
Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation. Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity. Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction with L3MBTL1 and leading to repress transcriptional activity. Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation.
Sumoylated by SUMO1. -
Cellular localization
Cytoplasm; Cytoplasm. Nucleus. Nucleus > PML body. Endoplasmic reticulum. Interaction with BANP promotes nuclear localization. Recruited into PML bodies together with CHEK2; Nucleus. Cytoplasm. Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli; Nucleus. Cytoplasm. Localized in the nucleus in most cells but found in the cytoplasm in some cells; Nucleus. Cytoplasm. Localized mainly in the nucleus with minor staining in the cytoplasm; Nucleus. Cytoplasm. Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4 and Nucleus. Cytoplasm. Predominantly nuclear but translocates to the cytoplasm following cell stress. - Information by UniProt
-
Database links
- Entrez Gene: 7157 Human
- Omim: 191170 Human
- SwissProt: P04637 Human
- Unigene: 654481 Human
-
Alternative names
- Antigen NY-CO-13 antibody
- BCC7 antibody
- Cellular tumor antigen p53 antibody
see all
Images
-
Immunocytochemistry/ Immunofluorescence - Anti-p53 antibody [Y5] (ab32049)Lab
ab32049 staining mutant p53 in wild-type Hap1 cells (top panel) and p53 knockout Hap1 cells (bottom panel). The cells were fixed with 4% paraformaldehyde (10 min), permeabilized with 0.1% PBS-Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated overnight at °C with ab32049 at 0.2µg/ml and ab7291, Mouse monoclonal [DM1A] to alpha Tubulin - Loading Control. Cells were then incubated with ab150081, Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (Alexa Fluor® 488), pre-adsorbed at 1/1000 dilution (shown in green) and ab150120, Goat polyclonal Secondary Antibody to Mouse IgG - H&L (Alexa Fluor® 594), pre-adsorbed at 1/1000 dilution (shown in pseudocolour red). Nuclear DNA was labelled with DAPI (shown in blue).
Also suitable in cells fixed with 100% methanol (5 min).
Image was acquired with a high-content analyser (Operetta CLS, Perkin Elmer) and a maximum intensity projection of confocal sections is shown.
-
![Immunocytochemistry/ Immunofluorescence - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-18-anti-mutant-p53-tp53-y5-antibody-immunocytochemistry-a431-human.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-p53 antibody [Y5] (ab32049)Labab32049 staining mutant p53 in A431 cells. The cells were fixed with 100% methanol (5 min), permeabilized with 0.1% PBS-Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated overnight at 4°C with ab32049 at 0.2µ?g/ml and ab7291, Mouse monoclonal [DM1A] to alpha Tubulin - Loading Control. Cells were then incubated with ab150081, Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (Alexa Fluor® 488), pre-adsorbed at 1/1000 dilution (shown in green) and ab150120, Goat polyclonal Secondary Antibody to Mouse IgG - H&L (Alexa Fluor® 594), pre-adsorbed at 1/1000 dilution (shown in pseudocolour red). Nuclear DNA was labelled with DAPI (shown in blue).
Image was acquired with a high-content analyser (Operetta CLS, Perkin Elmer) and a maximum intensity projection of confocal sections is shown.
-
![Immunocytochemistry/ Immunofluorescence - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-19-anti-wild-type-wt-p53-tp53-y5-antibody-immunocytochemistry-hek293-human.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-p53 antibody [Y5] (ab32049)Labab32049 staining wild-type p53 in Hek293 cells (a high expressing cell line). The cells were fixed with 100% methanol (5 min), permeabilized with 0.1% PBS-Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated overnight at 4°C with ab32049 at 0.2µg/ml and ab7291, Mouse monoclonal [DM1A] to alpha Tubulin - Loading Control. Cells were then incubated with ab150081, Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (Alexa Fluor® 488), pre-adsorbed at 1/1000 dilution (shown in green) and ab150120, Goat polyclonal Secondary Antibody to Mouse IgG - H&L (Alexa Fluor® 594), pre-adsorbed at 1/1000 dilution (shown in pseudocolour red). Nuclear DNA was labelled with DAPI (shown in blue).
Also suitable in cells fixed with 4% paraformaldehyde (10 min).
Image was acquired with a high-content analyser (Operetta CLS, Perkin Elmer) and a maximum intensity projection of confocal sections is shown.
-
![Immunocytochemistry/ Immunofluorescence - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-20-anti-wild-type-wt-p53-tp53-y5-antibody-immunocytochemistry-mcf7-human.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-p53 antibody [Y5] (ab32049)Labab32049 staining wild-type p53 in MCF7 cells (a low expressing cell line). The cells were fixed with 100% methanol (5 min), permeabilized with 0.1% PBS-Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated overnight at 4°C with ab32049 at 0.2µg/ml and ab7291, Mouse monoclonal [DM1A] to alpha Tubulin - Loading Control. Cells were then incubated with ab150081, Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (Alexa Fluor® 488), pre-adsorbed at 1/1000 dilution (shown in green) and ab150120, Goat polyclonal Secondary Antibody to Mouse IgG - H&L (Alexa Fluor® 594), pre-adsorbed at 1/1000 dilution (shown in pseudocolour red). Nuclear DNA was labelled with DAPI (shown in blue).
Also suitable in cells fixed with 4% paraformaldehyde (10 min).
Image was acquired with a high-content analyser (Operetta CLS, Perkin Elmer) and a maximum intensity projection of confocal sections is shown.
-
![Western blot - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-500329-Anti-p53-antibody-y5-western-blot-human.jpg)
Western blot - Anti-p53 antibody [Y5] (ab32049)All lanes : Anti-p53 antibody [Y5] (ab32049) at 1/1000 dilution
Lane 1 : Saos-2 cell lysate
Lane 2 : A431 cell lysate
Lane 3 : Wild-type HAP1 cell lysate
Lane 4 : TP53 knockout HAP1 cell lysate
Lane 5 : MCF7 cell lysate
Lane 6 : HEK-293T cell lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 44 kDa
Observed band size: 50 kDa why is the actual band size different from the predicted?False colour image of Western blot: Anti-p53 antibody [Y5] staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab32049 was shown to bind specifically to p53. A band was observed at 50 kDa in wild-type HAP1 cell lysate with no signal observed at this size in tp53 knockout cell line. To generate this image, wild-type and tp53 knockout HAP1 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.
-
![Western blot - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-397460-AntiMutant-p53-antibody.png)
Western blot - Anti-p53 antibody [Y5] (ab32049)All lanes : Anti-p53 antibody [Y5] (ab32049) at 1/10000 dilution
Lane 1 : A431 (Human epidermoid carcinoma epithelial cell), Whole cell lysate
Lane 2 : A549 (Human lung carcinoma epithelial cell), Whole cell lysate
Lane 3 : MCF-7 (Human breast adenocarcinoma epithelial cell), Whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/20000 dilution
Predicted band size: 44 kDa
Exposure time: 180 secondsBlocking/Diluting buffer and concentration: 5% NFDM/TBST
Lane1: Mutant p53 cell lines
Lane2-3: Wildtype p53 cell lines
Exposure time: 180 seconds
Observed MW: 50KDa
-
![Western blot - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-397459-AntiMutant-p53-antibody.png)
Western blot - Anti-p53 antibody [Y5] (ab32049)All lanes : Anti-p53 antibody [Y5] (ab32049) at 1/500 dilution
Lane 1 : HepG2 (Human hepatocellular carcinoma epithelial cell), Whole cell lysate
Lane 2 : A549(Human lung carcinoma epithelial cell), Whole cell lysate
Lane 3 : MCF-7(Human breast adenocarcinoma epithelial cell), Whole cell lysate
Lane 4 : U-87 MG (Human glioblastoma-astrocytoma epithelial cell), Whole cell lysate
Lane 5 : MDA-MB-435(Human mammary gland ductal carcinoma melanocyte), Whole cell lysate
Lane 6 : T-47D (Human ductal breast epithelial tumor epithelial cell), Whole cell lysate
Lane 7 : Raji (Human Burkitt's lymphoma B lymphocyte), Whole cell lysate
Lane 8 : Ramos (Human Burkitt's lymphoma B lymphocyte), Whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/20000 dilution
Predicted band size: 44 kDa
Exposure time: 60 secondsBlocking/Diluting Buffer and concentration: 5% NFDM/TBST
Lane 1-4: Wildtype p53 cell lines
Lane 5-8: Mutant p53 cell lines
Observed MW: 50 kDa
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-43735-anti-mutant-p53-antibody-y5-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p53 antibody [Y5] (ab32049)ab32049 showing positive staining in Urinary bladder carcinoma tissue.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
![Flow Cytometry (Intracellular) - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-268753-anti-mutant-p53-antibody-y5-flow-cytometry.jpg)
Flow Cytometry (Intracellular) - Anti-p53 antibody [Y5] (ab32049)Intracellular Flow Cytometry analysis of A431 (human epidermoid carcinoma) cells labeling Mutant p53 with unpurified ab32049 at 1/20 dilution (10ug/ml) (red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat anti rabbit IgG (Alexa Fluor® 488) (1/2000) was used as the secondary antibody. Rabbit monoclonal IgG (Black) was used as the isotype control, cells without incubation with primary antibody and secondary antibody (Blue) was used as the unlabeled control.
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-43738-anti-mutant-p53-antibody-y5-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p53 antibody [Y5] (ab32049)Immunohistochemistry (Paraffin-embedded sections) using ab32049 at a dilution of 1/50 and human skin cancer
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-43737-anti-mutant-p53-antibody-y5-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p53 antibody [Y5] (ab32049)ab32049 showing positive staining in Glioma tissue.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-43736-anti-mutant-p53-antibody-y5-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p53 antibody [Y5] (ab32049)ab32049 showing positive staining in Gastric adenocarcinoma tissue.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-43734-anti-mutant-p53-antibody-y5-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p53 antibody [Y5] (ab32049)ab32049 showing positive staining in Breast carcinoma tissue.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-228266-anti-mutant-p53-antibody-y5-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p53 antibody [Y5] (ab32049)Immunohistochemical analysis of paraffin embedded normal Human breast tissue (negative control) labeling p53 with ab32049.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-228267-anti-mutant-p53-antibody-y5-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-p53 antibody [Y5] (ab32049)Immunohistochemical analysis of paraffin embedded normal Human uterus tissue (negative control) labeling p53 with ab32049.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
![Immunoprecipitation - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-15-anti-mutant-p53-antibody-y5-immunoprecipitation-a431-human.jpg)
Immunoprecipitation - Anti-p53 antibody [Y5] (ab32049)Mutant p53 was immunoprecipitated from 0.35 mg A431 (Human epidermoid carcinoma epithelial cell) whole cell lysate 10 µg with ab32049 at 1/100 dilution (2µg) . VeriBlot for IP Detection Reagent (HRP)(ab131366) was used at 1/5000 dilution.
Lane 1: A431 (Human epidermoid carcinoma epithelial cell) whole cell lysate 10 µg
Lane 2: ab32049 IP in A431 whole cell lysate
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab32049 in A431 whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
-
![OI-RD Scanning - Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-43733-anti-mutant-p53-antibody-y5.jpg)
OI-RD Scanning - Anti-p53 antibody [Y5] (ab32049) -
![Anti-p53 antibody [Y5] (ab32049)](https://www.abcam.com/ps/products/32/ab32049/Images/ab32049-14-benefits-of-recombinant-antibodies.png)
Anti-p53 antibody [Y5] (ab32049)
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (47)
ab32049 has been referenced in 47 publications.
- Huang Y et al. The intracellular domain of UNC5B facilities proliferation and metastasis of bladder cancer cells. J Cell Mol Med 25:2121-2135 (2021). PubMed: 33345442
- Purwanto I et al. MicroRNA-223 is Associated with Resistance Towards Platinum-based Chemotherapy and Worse Prognosis in Indonesian Triple-negative Breast Cancer Patients. Breast Cancer (Dove Med Press) 13:1-7 (2021). PubMed: 33442288
- Nannapaneni S et al. Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma. PLoS One 16:e0247498 (2021). PubMed: 33626078
- Xu S et al. LSD1 silencing contributes to enhanced efficacy of anti-CD47/PD-L1 immunotherapy in cervical cancer. Cell Death Dis 12:282 (2021). PubMed: 33731702
- da Fonseca LG et al. Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity. Oncotarget 12:440-449 (2021). PubMed: 33747359